一二三四区视频,亚洲少妇熟女色,日本久热无码视频网,欧美国产日韩大尺度,亚洲a视频,久久少妇一区二区,日韩999无码视频,刺激久久久久久久,啊啊啊啊不要啊在线

返回ChemicalBook首頁>CAS數(shù)據(jù)庫列表>1370651-20-9

1370651-20-9

中文名稱 561.44
英文名稱 C26H27Cl2FN6O3
CAS 1370651-20-9
分子式 C26H27Cl2FN6O3
分子量 561.44
MOL 文件 1370651-20-9.mol
更新日期 2026/02/09 21:54:43
1370651-20-9 結構式 1370651-20-9 結構式

基本信息

中文別名
愛沙替尼
英文別名
561.44
C26H27Cl2FN6O3
Ensartinib (X-396)
X396
X-396
X 396
ENSARTINIB

3-Pyridazinecarboxamide, 6-amino-5-[(1R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy]-N-[4-[[(3R,5S)-3,5-dimethyl-1-piperazinyl]carbonyl]phenyl]-

物理化學性質

儲存條件-20°C儲存
溶解度溶于二甲基亞砜

安全數(shù)據(jù)

危險性符號(GHS)有害 (GHS07)
GHS07
警示詞警告
危險性描述H302-H315-H319-H335
恩沙替尼價格(試劑級)
報價日期產品編號產品名稱CAS號包裝價格
2026/06/05HY-103714恩沙替尼
Ensartinib
1370651-20-91 mg600元
2026/06/05HY-103714恩沙替尼
Ensartinib
1370651-20-95 mg1500元
2026/06/05HY-103714恩沙替尼
Ensartinib
1370651-20-910 mM * 1 mL in DMSO1853元

常見問題列表

生物活性
Ensartinib (X-396) 是一種有效的雙重的 ALK/MET 抑制劑,IC50 分別 <0.4 nM 和 0.74 nM。
靶點

MET

0.74 nM (IC 50 )

體外研究

The ability of Ensartinib (X-396) to inhibit the growth of different cancer cell lines harboring ALK fusions or point mutations is tested. Ensartinib is potent in H3122 lung cancer cells harboring EML4-ALK E13;A20 (IC 50 : 15nM). Ensartinib is also potent in H2228 lung cancer cells harboring EML4-ALK E6a/b; A20 (IC 50 : 45 nM). Furthermore, X-376 is potent in SUDHL-1 lymphoma cells harboring NPM-ALK (IC 50 : 9 nM). X-376 also inhibits SY5Y neuroblastoma cells harboring ALK F1174L, MKN-45 gastric carcinoma cells harboring MET dependent, HepG2 cells and PC-9 lung cancer cell lines harboring EGFR exon 19 del with IC 50 s of 68 nM, 156 nM, 9.644 μM and 2.989 μM, respectively.

體內研究

The effects of Ensartinib (X-396) in vivo against H3122 xenografts are examined. A pharmacokinetic study reveals that Ensartinib shows substantial bioavailability and moderate half-lives in vivo. Nude mice harboring H3122 xenografts are treated with Ensartinib at 25mg/kg bid. Ensartinib significantly delays the growth of tumors compared to vehicle alone. In the xenograft experiments, Ensartinib appears well-tolerated in vivo. Mouse weight is unaffected by Ensartinib treatment. Drug-treated mice appear healthy and do not display any signs of compound related toxicity. To further assess potential side effects of Ensartinib, additional systemic toxicity and toxico-kinetic studies are performed in Sprague Dawley (SD) rats. Following 10 days of repeated oral administration of Ensartinib at 20, 40, 80 mg/kg in SD rats, all animals survive to study termination. The no significant toxicity (NST) levels are determined to be 80mg/kg for Ensartinib. At NST levels, Ensartinib achieves an AUC of 66 μM×hr and a C max of 7.19 μM.

"1370651-20-9" 相關產品信息
215294-98-7 2404756-81-4 2455518-33-7 861128-90-7
石柱| 昌图县| 邵东县| 雅安市| 庆云县| 岳普湖县| 抚远县| 湄潭县| 读书| 遂平县| 黔东| 依安县| 石首市| 鹿泉市| 石首市| 姚安县| 新河县| 藁城市| 芷江| 洞头县| 崇义县| 巨野县| 三亚市| 海南省| 平阴县| 南昌县| 牙克石市| 镇平县| 乌兰察布市| 普兰店市| 浑源县| 平南县| 建瓯市| 大同县| 改则县| 陆川县| 道孚县| 巫溪县| 姜堰市| 德钦县| 福安市|